Tegoprazan is a novel orally active potassium-competitive acid blocker (P-CAB), capable of
binding to the K+ binding site of H+/K+-ATPase in a reversible way to inhibit gastric acid …

Tegoprazan is a novel potassium-competitive acid blocker (P-CAB) recently approved in
Korea as a next-generation therapeutics for gastric acid-related diseases. In the present …

Tegoprazan, a novel potassium-competitive acid blocker (P-CAB), is a next-generation
therapeutics developed for the treatment of acid-related gastrointestinal diseases such as …

Potassium-competitive acid blockers (P-CABs), such as tegoprazan, are a new and diverse
class of drugs that can completely block the potassium-binding site of gastric H+/K+ ATPase …

Summary Background Tegoprazan (CJ‐12420) is a potassium‐competitive acid blocker (P‐
CAB) with therapeutic potential for gastro‐oesophageal reflux disease (GERD) by reversibly …

Aims The new modified‐release formulation of tegoprazan, a novel potassium‐competitive
acid blocker, is expected to improve the management of acid‐related disease, including …

Tegoprazan, a selective potassium-competitive acid blocker, was approved in 2018 in the
Republic of Korea for the treatment of gastroesophageal reflux disease (GERD), erosive …

Background CJ-12420 (tegorazan) is a promising potassium-competitive acid blocker (P-
CAB) with therapeutic potential for gastroesophageal reflux disease (GERD) by reversibly …

Proton-pump inhibitors (PPIs) are effectively used to treat acid-related diseases, including
gastroesophageal reflux disease (GERD); however, many unmet medical needs still exist …

Tegoprazan, a novel potassium‐competitive acid blocker, is used to treat acid‐related
diseases. However, there is no information on the pharmacokinetic (PK) and …